{
    "clinical_study": {
        "@rank": "124286", 
        "arm_group": [
            {
                "arm_group_label": "Testogel 1% 5g QD", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo gel 5g QD", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of Testogel\u00ae 50mg/5g gel\n      administered once daily (QD, morning dosing) compared to placebo administered once daily\n      (QD, morning dosing), for 3 months, in hypogonadal men with testosterone deficiency being\n      confirmed by clinical features and biochemical tests. For men with hypogonadism, treatment\n      aims to restore testosterone levels to normal physiological range."
        }, 
        "brief_title": "Testogel\u00ae (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism", 
        "condition": "Hypogonadism", 
        "condition_browse": {
            "mesh_term": [
                "Hypogonadism", 
                "Eunuchism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male ages 18-68 years diagnosed as having testosterone deficiency with clinical\n             symptoms\n\n          -  A morning (8:00-10:00) serum Total Testosterone concentration of  \u2264 300 ng/dL,\n             confirmed by a second measurement of morning serum Total Testosterone concentration \u2264\n             300 ng/dL (samples to be taken 1 - 3 weeks apart)\n\n        Exclusion Criteria:\n\n          -  Abnormal prostate as evidenced by prostatic symptoms, prostatic masses or induration\n             on rectal examination, or elevated levels of prostate specific antigen (PSA \uff1e 4ng/ml)\n             or a maximum urine flow rate of less than 12 ml/sec(of a urine volume greater than\n             150ml) (and/or an International Prostate Symptom  Score IPSS score >19)\n\n          -  Hematocrit > 50%\n\n          -  Major psychiatric illness\n\n          -  Unable to understand the protocol or to give informed consent\n\n          -  Use of paroxetine and clomipramine\n\n          -  Active alcoholism\n\n          -  History of drug abuse within the past five years;\n\n          -  Use of drugs that might interfere with the results of the study (e.g., antiandrogen,\n             estrogens or P 450 enzyme inducers, barbiturates);\n\n          -  BMI < 18 or  > 30 according to Chinese BMI references;\n\n          -  Generalized skin disease that may affect absorption of T (e.g., psoriasis) or a known\n             skin intolerance to alcohol;\n\n          -  Prolactin > 40 mcg/L;\n\n          -  Untreated severe obstructive sleep apnea;.\n\n          -  Uncontrolled or poorly controlled heart failure"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "68 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01786473", 
            "org_study_id": "01BHR11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Testogel 1% 5g QD", 
                "intervention_name": "Testogel 1%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo gel 5g QD", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Peking", 
                    "country": "China"
                }, 
                "name": "Peking University First Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Double Blind, Randomized, Placebo Controlled Study of Testogel\u00ae (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism", 
        "overall_contact": {
            "email": "edhoore@besins-healthcare.com", 
            "last_name": "Ellen Dhoore"
        }, 
        "overall_official": {
            "affiliation": "Peking University First Hospital", 
            "last_name": "Jie Jin", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: SFDA", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with morning serum Total Testosterone concentration within the physiological range (300 - 1000 ng/dL or 10.4 - 34.7 nmol/L) after 3 months of Testogel treatment compared to placebo-treatment", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01786473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "morning serum Total Testosterone (TT) concentration compared to placebo treatment", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "morning serum Total Testosterone (TT) concentration compared to baseline values", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "serum concentrations of TT, calculated free testosterone (cFT), DHT, E2, LH, and FSH, SHBG", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "prostate assessments (PSA, urine flow rate, DRE, ultrasound B)", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "skin integrity", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Laboratoires Besins International", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratoires Besins International", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}